Home Cart Sign in  
Chemical Structure| 1849590-01-7 Chemical Structure| 1849590-01-7

Structure of Tomivosertib
CAS No.: 1849590-01-7

Chemical Structure| 1849590-01-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

eFT508 is a potent, highly selective MNK1 and MNK2 inhibitor with IC50 value of 1-2 nM.

Synonyms: eFT508

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tomivosertib

CAS No. :1849590-01-7
Formula : C17H20N6O2
M.W : 340.38
SMILES Code : O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4
Synonyms :
eFT508
MDL No. :MFCD30489732
InChI Key :HKTBYUWLRDZAJK-UHFFFAOYSA-N
Pubchem ID :118598754

Safety of Tomivosertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tomivosertib

MAPK

Isoform Comparison

Biological Activity

Target
  • MNK2

    MNK2, IC50:1 nM

  • MNK1

    MNK1, IC50:2.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 IC50 = 0.31 ± 0.02 nM 24 hours Evaluate the chemosensitivity of MDA-MB-231 cells to Tomivosertib, showing that this cell line is significantly more sensitive to Tomivosertib compared to other cell lines. PMC9206753
MDA-MB-468 IC50 = 1.21 ± 0.01 nM 24 hours Evaluate the chemosensitivity of MDA-MB-468 cells to Tomivosertib, showing that this cell line is significantly more sensitive to Tomivosertib compared to other cell lines. PMC9206753
MCF7 IC50 = 11.38 ± 1.02 nM 24 hours Evaluate the chemosensitivity of MCF7 cells to Tomivosertib, showing that this cell line is significantly more sensitive to Tomivosertib compared to other cell lines. PMC9206753
T47D IC50 = 10.19 ± 0.01 nM 24 hours Evaluate the chemosensitivity of T47D cells to Tomivosertib, showing that this cell line is significantly more sensitive to Tomivosertib compared to other cell lines. PMC9206753
SUM149 IC50 = 9.14 ± 0.14 nM 24 hours Evaluate the chemosensitivity of SUM149 cells to Tomivosertib, showing that this cell line is significantly more sensitive to Tomivosertib compared to other cell lines. PMC9206753
Mouse dorsal root ganglion (DRG) neurons 25 nM 3 hours Tomivosertib significantly reduced spontaneous firing induced by IL-6 treatment, indicating its ability to reduce abnormal neuronal activity. PMC6969143
CoCaB1, CoCaB14.1, and TM01029 organoids 0.01–10 μM 72 hours To study the effect of eFT508 on high phospho-eIF4E bladder cancer organoids, results showed that high phospho-eIF4E organoids exhibited a dose-dependent decrease in cell viability in response to eFT508, while low phospho-eIF4E organoids showed no response. PMC8262354

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Peripheral nerve injury (PNI) model Oral (p.o.) or intraperitoneal (i.p.) 10 mg/kg Once daily for 7 days Tomivosertib reversed spontaneous pain and cognitive dysfunction in PNI mice by inhibiting the MNK-eIF4E signaling pathway, and it restored the length of axon initial segments in the prefrontal cortex. PMC6969143
Mice Fmr1−/− mouse model Intraperitoneal injection 1 mg/kg, 3 mg/kg, 5 mg/kg, 8 mg/kg Once daily for 4 days Tomivosertib (eFT508) reduces eIF4E phosphorylation by inhibiting MNK activity and ameliorates behavioral and physiological deficits associated with FXS in Fmr1?/? mice. PMC8116363
Mice CoCaB1 and TM01029 PDX models Oral 10 mg/kg Once daily until the end of the experiment To study the effect of eFT508 on high phospho-eIF4E PDX models, results showed that high phospho-eIF4E models were sensitive to eFT508, with significantly smaller tumor size and improved survival, while low phospho-eIF4E models showed no response. PMC8262354
BALB/c mice Orthotopic xenograft model IntratumOral injection 1 mg/kg/day Once daily for 8 weeks Evaluate the in vivo chemosensitivity of Tomivosertib in breast tumor xenografts, showing that both monotherapy and combination therapy with adriamycin significantly inhibited tumor growth and lung metastasis. PMC9206753

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03690141 Castrate-resistant Prostate Ca... More >>ncer (CRPC) Less << PHASE2 TERMINATED 2020-04-27 Yale Cancer Center, New Haven,... More >> Connecticut, 06510, United States|Northwestern University, Chicago, Illinois, 60611, United States|Kimmel Center at Johns Hopkins, Baltimore, Maryland, 21205, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Washington University, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|The Urology Group, Cincinnati, Ohio, 45212, United States|Lancaster Urology, Lancaster, Pennsylvania, 17604, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|University of Washington, Seattle, Washington, 89109, United States Less <<
NCT03318562 Triple Negative Breast Cancer|... More >>Hepatocellular Carcinoma Less << PHASE2 TERMINATED 2019-01-22 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Kansas City Research Institute, Kansas City, Missouri, 64131, United States Less <<
NCT02605083 Cancer PHASE1|PHASE2 TERMINATED 2019-03-22 SCRI at HealthONE, Denver, Col... More >>orado, 80218, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.94mL

0.59mL

0.29mL

14.69mL

2.94mL

1.47mL

29.38mL

5.88mL

2.94mL

References

 

Historical Records

Categories